SULFATE AMPOULE 1ML/0.1%
SULFATE VIALS 10 ML 1%
Atropine sulfate 0.1 % /l ml in one ampoule and 1 %/10 ml
isotonic solution (collyr).
Atropine is an alkaloid from Atropa belladonna L. it blocks the
M-cholinoreceptors and disturbs the transmission of nerve impulses
from the postganglionic cholinergic nerves to the effector organs:
salivary, bronchial and sudoriferous glands, heart, smooth muscles
of the digestive system and eyes. It has a slight effect on the
N-cholinergic receptors in therapeutic doses.
Atropine inhibits the secretion of the sudoriferous, salivary,
gastric and bronchial glands, and of pancreas. It reduces the tone
of the bronchial muscles, relaxes the smooth muscles of the
gastrointestinal tract, biliary and urinary ducts. It dilates pupils
and induces paralysis of accomodation. Its central M-cholinolytic
action is associated with reduction of tremor and decrease of muscle
tone in parkinsonism, excites respiration and in high doses
paralyses the respiratory center. It accelerates cardiac rhythm and
improves the His bundle conductivity.
It is well absorbed after oral administration, its plasma half-life
is from 18 to 38 h, and its binding to plasma proteins is about 50%.
Administered in the complex therapy of ulcer disease, pylorospasm,
cholecystitis, cholelithiasis, gastric, biliary and renal colic,
bronchial asthma, etc. for treatment of acute intoxications with
cholinomimetics, postencephalic parkinsonism, digitalis
intoxications, etc. it is used with diagnostic and therapeutic
purpose for inducing mydriasis and paralysis of eye accomodation.
Its application is contraindicated in glaukoma, hypertrophy of
prostate and postoperative paresis of the urinary bladder and
intestines, active form of pulmonary tuberculosis and cardiac
It induces specific, so-called atropine-like side effects: dryness
in the mouth, mydriasis, increased ophthalmotone, palpitation,
obstipation and urine retention. In high doses it can induce motor
and psychic excitation, hallucinations, convulsions and arterial
Atropine reduces the analgesic action of opiates. The toxic action
of MAO-inhibitors is potentiated in combined therapy (tachycardia
and arrhythmia); with digitalis drugs it contributes to the disorder
of the cardiac rhythm. Potentiates the cholinolytic effect of
chinidine and novocainamide. It antagonizes the M-cholinomimetic
effect of nivalin, pilocarpine, neostigmine, etc.
DOSAGE AND ADMINISTRATION:
Collyr - topically applied. For cycloplegia - 1-2 drops, two times
daily until the desired effect is attained (3-5 days on the
average); therapeutically - it is applied in the lower conjunctival
sac - 1-2 drops, 2-5 times daily.
Ampoules: parenterally injected - subcutaneously, intramuscularly or
intravenously in doses from 0.25 to 1 mg, 1-3 times daily. The
maximum daily dose for adults is 3 mg. Atropine can be applied every
15 min in doses of 1 mg intramuscularly or intravenously in
intoxication with phosphororganic compounds.
MEDICINAL FORM AND PACKAGE:
Packages with 10 and 50 ampoules of 1 ml/0.1 %.
Vials of 10 ml with eye drops of 1 %.
At moderate temperature (15-30° C).
5 (five) years.